Denali Therapeutics Inc DNLI
$24.92 $0.03 (0.12%) 1D
Last Updated: Aug 21, 12:00 AM·NASDAQ
Pricing for US stocks is delayed by 24 hours
DNLI Shariah Compliance
Screening Methodology: AAOIFI
As of August 2026, Denali Therapeutics Inc is classified as not halal.
NOT HALAL
Report Source: undefined Quarter Report
Denali Therapeutics Inc. Stock Analysis DNLI
United States Health Care Mid Cap Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. The company is headquartered in South San Francisco, California and currently employs 503 full-time employees. The company went IPO on 2017-12-08. The company is focused on building a portfolio of therapeutic candidates by investing in its TV franchises, i.e., Enzyme TV (ETV), Oligonucleotide TV (OTV), and Antibody TV (ATV), to advance programs for rare diseases, such as lysosomal storage diseases, and common diseases, such as Alzheimer's disease and Parkinson's disease. Its most advanced TV-enabled program is tividenofusp alfa (DNL310, ETV:IDS) for the potential treatment of mucopolysaccharidosis II (Hunter syndrome). TV-enabled clinical development portfolio also includes DNL126 (ETV:SGSH) for mucopolysaccharidosis IIIA (Sanfilippo syndrome type A), DNL593 (PTV:PGRN) for frontotemporal dementia-granulin, DNL628 (OTV:MAPT) for Alzheimer’s disease, and DNL952 (ETV:GAA) for Pompe disease. The company is also pursuing opportunities in other disease areas including oncology.
Denali Therapeutics Inc (DNLI) Chart
Financial Metrics & Statements of Denali Therapeutics Inc (DNLI)
FAQ's for Denali Therapeutics Inc (DNLI)
- As of August 2026, Denali Therapeutics Inc DNLI is classified as not halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Denali Therapeutics Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Denali Therapeutics Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Denali Therapeutics Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Denali Therapeutics Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Denali Therapeutics Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.
Alternate Halal Stocks for Denali Therapeutics Inc (DNLI)
Related Halal Stocks are Shariah-compliant companies that align with Islamic investment principles, avoiding prohibited industries like alcohol, gambling, and interest-based finance.
